Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
, V3 a. ^9 P$ x! m4 HNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
. y3 H/ Z) {9 j+ Author Affiliations, k3 H# p& y. M9 p6 Z& `
$ A2 T% O, \, i6 E9 N1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! N& j& n" W. M+ s' Z/ w! p2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& R$ r0 D5 U& N3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan - {6 {1 B# ?; ]6 L
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 7 R5 e) U5 F+ k8 }
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, ~- X" J: E# h3 s; f6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan # y/ ~6 ^% d, L( T/ x
7Kinki University School of Medicine, Osaka 589-8511, Japan
% n& D1 i2 g l, _( Q8 Q0 S/ \" t# Y8Izumi Municipal Hospital, Osaka 594-0071, Japan
) b# g- k5 q6 \( b. a9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( ~* `/ e; h1 QCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp . Z' K- m7 o+ L
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
: l9 g, ^) L1 h; t4 M
- N( v1 s5 N7 v+ d+ k9 z; R |